Previous 10 | Next 10 |
Alimera Sciences (NASDAQ:ALIM) its partner Ocumension Therapeutics received approval from China's National Medical Products Administration (NMPA) for an application seeking to begin a phase 3 trial of fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). DME is a ...
ATLANTA, June 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced t...
ATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced tod...
Alimera Sciences, Inc (ALIM) Q1 2022 Earnings Conference Call May 09, 2022, 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital ...
Alimera Sciences press release (NASDAQ:ALIM): Q1 GAAP EPS of -$0.85 misses by $0.16. Revenue of $11.89M (+6.1% Y/Y) misses by $1.01M. For further details see: Alimera Sciences GAAP EPS of -$0.85 misses by $0.16, revenue of $11.89M misses by $1.01M
Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 U.S. Net Revenue Increased 23% vs. First Quarter of 2021 U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc....
ATLANTA, May 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will ...
ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announ...
Shares of Alimera Sciences Inc. (NASDAQ:ALIM) traded at a new 52-week high today of $13.50. Approximately 28.5 million shares have changed hands today, as compared to an average 30-day volume of 33,000 shares. Alimera Sciences Inc. (NASDAQ:ALIM) defies analysts with a current price ($6.0...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...